Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tonsillitis II: Management01:26

Tonsillitis II: Management

430
This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
430
Impression Management Techniques I: Managing Appearances01:29

Impression Management Techniques I: Managing Appearances

218
Appearance is a multidimensional aspect of self-presentation that encompasses observable attributes such as clothing, grooming, speech, and nonverbal behavior. These elements are often strategically managed to align with socially constructed expectations in different settings. For instance, individuals tailor their appearance during job interviews, social gatherings, or athletic events to meet the perceived norms of those environments.Contextual Adaptation and Social SignalsThe research...
218
Managing Impressions01:19

Managing Impressions

173
Impression management encompasses individuals' deliberate efforts to shape how others perceive them during social interactions. This behavior is often employed to conform to social norms, secure approval, or pursue specific goals. While it involves selective self-presentation, it is not necessarily deceptive; individuals frequently present authentic aspects of themselves that align with situational demands.Common strategies include:Ingratiation: where individuals use flattery or agreeableness...
173
Management of Insomnia01:19

Management of Insomnia

647
The sleep cycle, an integral part of human health, consists of several stages with distinct characteristics and functions. It begins with a transition from wakefulness to sleep, known as the light sleep phase, followed by the restorative deep sleep phase, essential for physical recovery and growth. The cycle concludes with the Rapid Eye Movement (REM) phase, characterized by high brain activity and vivid dreaming. Insomnia, a prevalent sleep disorder, involves difficulty falling asleep, staying...
647
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

543
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
543
Angina IV: Management01:26

Angina IV: Management

291
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
291

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

LySeqST: a targeted sequencing assay for robust genomic classification of diffuse large B-cell lymphoma.

Blood advances·2026
Same author

Diagnosis-to-treatment interval is associated with outcomes in follicular lymphoma treated with immunochemotherapy.

Blood·2026
Same author

Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.

Blood·2026
Same author

Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis.

American journal of hematology·2026
Same author

Bleomycin omission in limited-stage classic Hodgkin lymphoma with negative PET scan after two cycles of ABVD.

Haematologica·2026
Same author

Optimizing bridging radiotherapy prior to CAR-T cell therapy: An evidence-based approach.

Critical reviews in oncology/hematology·2026

Related Experiment Video

Updated: Feb 5, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

697

Management of relapsed/refractory DLBCL.

Clémentine Sarkozy1, Laurie H Sehn2

  • 1Cancer Center of Lyon (CRCL), INSERM U1052 - CNRS UMR5286, Lyon, France; British Columbia Cancer Centre for Lymphoid Cancer and the University of British Columbia, Vancouver, British Columbia, Canada.

Best Practice & Research. Clinical Haematology
|September 15, 2018
PubMed
Summary

Relapsed or refractory diffuse large B cell lymphoma (DLBCL) affects 40% of patients. Transplant-ineligible patients require individualized management and novel agents for better outcomes.

Keywords:
Diffuse large B cell lymphomaRefractoryRelapseTreatment

More Related Videos

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations
04:46

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations

Published on: February 24, 2023

2.3K
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

11.1K

Related Experiment Videos

Last Updated: Feb 5, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

697
Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations
04:46

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations

Published on: February 24, 2023

2.3K
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

11.1K

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Diffuse large B cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma.
  • While curable, approximately 40% of patients experience relapse or refractory disease.
  • Current standard care for relapsed DLBCL involves salvage chemotherapy and autologous stem cell transplant (ASCT).

Purpose of the Study:

  • To review the incidence, outcomes, and current management strategies for relapsed and refractory DLBCL.
  • To explore the therapeutic challenges and potential of novel agents in transplant-ineligible patients.
  • To provide an overview of emerging treatments for patients with relapsed or refractory DLBCL.

Main Methods:

  • This is a review article, synthesizing existing literature on relapsed and refractory DLBCL.
  • The review discusses epidemiological data, treatment outcomes, and clinical management approaches.
  • It also examines novel therapeutic agents currently under investigation for DLBCL.

Main Results:

  • A significant proportion of DLBCL patients relapse or become refractory to initial treatment.
  • Autologous stem cell transplant is standard for eligible relapsed patients, but over 60% are ineligible.
  • Management for transplant-ineligible patients is individualized, with novel agents showing promise.

Conclusions:

  • Relapsed and refractory DLBCL poses a significant clinical challenge, particularly for transplant-ineligible patients.
  • Individualized treatment strategies and the exploration of novel agents are crucial for improving outcomes.
  • Further research into novel therapies is essential for this patient population.